Assembly of Polynesia Approves Medical Cannabis Legalization

The Assembly of Polynesia has approved a bill to regulate medical cannabis for improved patient access to by the end of 2024, with an initial pilot phase involving a limited number of industrial players. The legislation differentiates between therapeutic cannabis and CBD, establishes a controlled local production chain from THC-free seeds, and includes ongoing evaluation of the law’s impact.

The legalization of medical cannabis in Fenua is making significant progress. Representatives of the Assembly of Polynesia recently approved the bill regulating “certain activities related to cannabis without narcotic properties and medicines containing cannabis or cannabinoids,” with 41 votes in favor and 16 abstentions. This legislative initiative aligns with the commitment made by Moetai Brotherson to ensure that patients in need can access therapeutic cannabis by the end of 2024.

For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.

Regulatory Framework and Implementation

The approved legislation lays the foundation for the cultivation and regulation of cannabis in Polynesia, initially focusing on a pilot phase. This initial phase will involve a limited number of industrial players to define the types of products to be prescribed before expanding the sector to others.

The Polynesian Cannabis Union (SPC), led by Philippe Cathelain, has been one of the main advocates for this progress. Mr. Cathelain expressed satisfaction with the Assembly’s decision, recognizing the significant efforts made over four years to reach this stage. He noted that while the initial text is not perfect, it is a crucial starting point that will allow for amendments and improvements through practical tests in Polynesia.

Distinction Between Therapeutic Cannabis and CBD in Polynesia

The bill, supported by the Ministries of Health and Agriculture in Polynesia, establishes a clear distinction between therapeutic cannabis and wellness cannabis. This distinction is based on French legislation, which allows a maximum THC content of 0.3% in the plant and the finished product.

Polynesian Health Minister Cédric Mercadal emphasized the importance of semantic clarity to ensure the public understands that the legislation does not permit recreational use but aims to provide optimal medical assistance to patients.

The new legislation includes a plan for a Polynesian cannabis production chain from THC-free seeds, managed by “controlled farmers” to ensure a product free of pesticides and heavy metals, suitable particularly for CBD production. The Council of Ministers will determine the perimeters, locations, and specific cultivation methods through successive decrees. This controlled approach aims to guarantee the safety and quality of cannabis products available to patients.

Nicole Sanquer, a representative of the non-affiliated members, proposed that the law be reviewed after one year to assess its impact and effectiveness. Cédric Mercadal approved this proposal, emphasizing the need for continuous evaluation to measure the benefits for Polynesian patients and the production sector, ensuring good management of resources and regulations.

—

(Featured image by Damien Chaudet via Unsplash)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.